366 related articles for article (PubMed ID: 22722227)
1. Immune modulating peptides for the treatment and suppression of multiple sclerosis.
Badawi AH; Siahaan TJ
Clin Immunol; 2012 Aug; 144(2):127-38. PubMed ID: 22722227
[TBL] [Abstract][Full Text] [Related]
2. Animal models of central nervous system immune-mediated diseases: therapeutic interventions with bioactive peptides and mimetics.
Grigoriadis N; Tselios T; Deraos S; Orologas A; Deraos G; Matsoukas J; Mavromatis I; Milonas I
Curr Med Chem; 2005; 12(13):1513-9. PubMed ID: 15974984
[TBL] [Abstract][Full Text] [Related]
3. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond.
Aharoni R
Autoimmun Rev; 2013 Mar; 12(5):543-53. PubMed ID: 23051633
[TBL] [Abstract][Full Text] [Related]
4. Nano- and micro-based systems for immunotolerance induction in multiple sclerosis.
Pires LR; Marques F; Sousa JC; Cerqueira J; Pinto IM
Hum Vaccin Immunother; 2016 Jul; 12(7):1886-90. PubMed ID: 26890336
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides.
Fontoura P; Garren H; Steinman L
Int Rev Immunol; 2005; 24(5-6):415-46. PubMed ID: 16318989
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with COP-1 in multiple sclerosis.
Bornstein MB; Miller A; Slagle S; Weitzman M; Crystal H; Drexler E; Keilson M; Merriam A; Wassertheil-Smoller S; Spada V
Neurology; 1988 Jul; 38(7 Suppl 2):66-9. PubMed ID: 3290717
[TBL] [Abstract][Full Text] [Related]
7. Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.
Hartung HP; Kieseier BC; Hemmer B
J Neurol; 2005 Nov; 252 Suppl 5():v30-7. PubMed ID: 16254700
[TBL] [Abstract][Full Text] [Related]
8. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
[TBL] [Abstract][Full Text] [Related]
9. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
[TBL] [Abstract][Full Text] [Related]
10. Current immune therapies of autoimmune disease of the nervous system with special emphasis to multiple sclerosis.
Vass K
Curr Pharm Des; 2012; 18(29):4513-7. PubMed ID: 22612753
[TBL] [Abstract][Full Text] [Related]
11. Towards immunotherapeutic drugs and vaccines against multiple sclerosis.
Katsara M; Matsoukas J; Deraos G; Apostolopoulos V
Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):636-42. PubMed ID: 18604455
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for multiple sclerosis: basic insights for new clinical strategies.
Mouzaki A; Tselios T; Papathanassopoulos P; Matsoukas I; Chatzantoni K
Curr Neurovasc Res; 2004 Oct; 1(4):325-40. PubMed ID: 16181082
[TBL] [Abstract][Full Text] [Related]
13. Emerging immunopharmacological targets in multiple sclerosis.
Farjam M; Zhang GX; Ciric B; Rostami A
J Neurol Sci; 2015 Nov; 358(1-2):22-30. PubMed ID: 26440421
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system infections - a potential complication of systemic immunotherapy.
Hemmer B; Frohman E; Hartung HP; Stüve O
Curr Opin Neurol; 2006 Jun; 19(3):271-6. PubMed ID: 16702834
[TBL] [Abstract][Full Text] [Related]
15. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis and their application for new therapeutic strategies.
Martin R
J Neural Transm Suppl; 1997; 49():53-67. PubMed ID: 9266414
[TBL] [Abstract][Full Text] [Related]
16. The role of costimulation in autoimmune demyelination.
Racke MK; Ratts RB; Arredondo L; Perrin PJ; Lovett-Racke A
J Neuroimmunol; 2000 Jul; 107(2):205-15. PubMed ID: 10854658
[TBL] [Abstract][Full Text] [Related]
17. Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.
Chen SJ; Wang YL; Fan HC; Lo WT; Wang CC; Sytwu HK
Clin Dev Immunol; 2012; 2012():970789. PubMed ID: 22203863
[TBL] [Abstract][Full Text] [Related]
18. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
Warnke C; Olsson T; Hartung HP
Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: an altered immune response or an altered stress response?
van Noort JM
J Mol Med (Berl); 1996 Jun; 74(6):285-96. PubMed ID: 8862510
[TBL] [Abstract][Full Text] [Related]
20. The double-edged sword of autoimmunity: lessons from multiple sclerosis.
Hestvik AL
Toxins (Basel); 2010 Apr; 2(4):856-77. PubMed ID: 22069614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
